Compare NNVC & ELOX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NNVC | ELOX |
|---|---|---|
| Founded | 2005 | N/A |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 37.9M | 41.0M |
| IPO Year | 2008 | N/A |
| Metric | NNVC | ELOX |
|---|---|---|
| Price | $1.42 | $17.62 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 359.1K | 55.5K |
| Earning Date | 05-15-2026 | N/A |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 10.00 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.85 | $10.00 |
| 52 Week High | $2.23 | $19.36 |
| Indicator | NNVC | ELOX |
|---|---|---|
| Relative Strength Index (RSI) | 40.90 | 67.66 |
| Support Level | $1.13 | $10.74 |
| Resistance Level | $1.47 | $19.36 |
| Average True Range (ATR) | 0.12 | 2.00 |
| MACD | -0.03 | 0.72 |
| Stochastic Oscillator | 7.37 | 80.34 |
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.
Eloxx Pharmaceuticals Inc is a clinical-stage biopharmaceutical company engaged in developing novel, small-molecule product candidates designed to modulate the ribosome and promote readthrough of premature stop codons induced by nonsense mutations (NMs) to enable the production of full-length proteins. The exaluren, the company's investigational drug product for the treatment of rare kidney diseases, and, through the collaboration with Almirall, S.A. (Almirall), ZKN-013 for the treatment of rare skin diseases.